In continuation of our letter dated January 7, 2021 and pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, we enclose the Unaudited Financial Results Standalone and Consolidated for the quarter nine months ended December 31, 2020, duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

http://courses.ecornell.com/eportfolios/24644/Gp_Stan_Dx_100_Receiver__Geneza_Pharmaceuticals__Injectable_Steroids
http://epicentro.instructure.com/eportfolios/2230/Ipamorelin_Kuznetsova_Vs__Sinoway__Peptides
http://avhsd.instructure.com/eportfolios/1914/Gp_Proviron_Side_Effects_Spironolactone__Magnum_Pharmaceuticals__Oral_Steroids


縺ゅ縺
メッセージ